219 related articles for article (PubMed ID: 34285919)
21. Identification of CCT3 as a prognostic factor and correlates with cell survival and invasion of head and neck squamous cell carcinoma.
Wang Y; Liu P; Zhang Z; Wang J; Cheng Z; Fan C
Biosci Rep; 2021 Oct; 41(10):. PubMed ID: 34505628
[TBL] [Abstract][Full Text] [Related]
22. The prognostic value of faciogenital dysplasias as biomarkers in head and neck squamous cell carcinoma.
Ma C; Li H; Li X; Lu S; He J
Biomark Med; 2019 Nov; 13(16):1399-1415. PubMed ID: 31596126
[No Abstract] [Full Text] [Related]
23. Exostoisns (EXT1/2) in Head and Neck Cancers: An In Silico Analysis and Clinical Correlates.
Wang Y; Huang Y; Zhu H; Guo Z; Cheng J; Zhang C; Zhong M
Int Dent J; 2024 Jun; 74(3):446-453. PubMed ID: 37989698
[TBL] [Abstract][Full Text] [Related]
24. Expression and prognostic analysis of BGN in head and neck squamous cell carcinoma.
Zhao L; Liang J; Zhong W; Han C; Liu D; Chen X
Gene; 2022 Jun; 827():146461. PubMed ID: 35358652
[TBL] [Abstract][Full Text] [Related]
25. Integrated analysis of diagnostic, prognostic value and potential drug treatment of GSDME in head and neck squamous cell carcinoma.
Hu R; Lu M; She L
Eur Arch Otorhinolaryngol; 2023 Sep; 280(9):4239-4253. PubMed ID: 37204444
[TBL] [Abstract][Full Text] [Related]
26. High expression of CLEC10A in head and neck squamous cell carcinoma indicates favorable prognosis and high-level immune infiltration status.
Zou M; Wu H; Zhou M; Xiao F; Abudushalamu G; Yao Y; Zhao F; Gao W; Yan X; Fan X; Wu G
Cell Immunol; 2022 Feb; 372():104472. PubMed ID: 35093731
[TBL] [Abstract][Full Text] [Related]
27. Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer.
Jiang AM; Ren MD; Liu N; Gao H; Wang JJ; Zheng XQ; Fu X; Liang X; Ruan ZP; Tian T; Yao Y
Int J Med Sci; 2021; 18(1):226-238. PubMed ID: 33390791
[No Abstract] [Full Text] [Related]
28. DOCK8 Serves as a Prognostic Biomarker and Is Related to Immune Infiltration in Patients With HPV Positive Head and Neck Squamous Cell Carcinoma.
Zhang Z; Bao Y; Zhou L; Ye Y; Fu W; Sun C
Cancer Control; 2021; 28():10732748211011951. PubMed ID: 33910393
[TBL] [Abstract][Full Text] [Related]
29. SEC61G overexpression and DNA amplification correlates with prognosis and immune cell infiltration in head and neck squamous cell carcinoma.
Lu T; Chen Y; Gong X; Guo Q; Lin C; Luo Q; Tu Z; Pan J; Li J
Cancer Med; 2021 Nov; 10(21):7847-7862. PubMed ID: 34590792
[TBL] [Abstract][Full Text] [Related]
30. Integrated analysis of DNA methylation and mRNA expression profiles to identify key genes in head and neck squamous cell carcinoma.
Jin Y; Qin X
Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31894857
[TBL] [Abstract][Full Text] [Related]
31. Identification of Immune-Related Prognostic Biomarkers Associated with HPV-Positive Head and Neck Squamous Cell Carcinoma.
Chen Y; Nie J; Li X; Fan T; Deng X; Liang D; Song G
J Immunol Res; 2021; 2021():6661625. PubMed ID: 33506058
[TBL] [Abstract][Full Text] [Related]
32. Identification of Immune Subtypes for Predicting the Prognosis of Patients in Head and Neck Squamous Cell Carcinoma.
Sun J; Fang G; Zuo Z; Yu X; Xue L; Li C; Li S
Technol Cancer Res Treat; 2021; 20():15330338211045823. PubMed ID: 34657509
[TBL] [Abstract][Full Text] [Related]
33. FDCSP Is an Immune-Associated Prognostic Biomarker in HPV-Positive Head and Neck Squamous Carcinoma.
Wu Q; Shao T; Huang G; Zheng Z; Jiang Y; Zeng W; Lv X
Biomolecules; 2022 Oct; 12(10):. PubMed ID: 36291667
[No Abstract] [Full Text] [Related]
34. Identification of genetic mechanisms underlying lipid metabolism-mediated tumor immunity in head and neck squamous cell carcinoma.
Liu S; Wang S; Wang Z
BMC Med Genomics; 2023 May; 16(1):110. PubMed ID: 37210507
[TBL] [Abstract][Full Text] [Related]
35. Syntenin-1 is a promoter and prognostic marker of head and neck squamous cell carcinoma invasion and metastasis.
Cui L; Cheng S; Liu X; Messadi D; Yang Y; Hu S
Oncotarget; 2016 Dec; 7(50):82634-82647. PubMed ID: 27811365
[TBL] [Abstract][Full Text] [Related]
36. NUTF2 as a Prognostic Indicator and Potential Therapeutic Target in Head and Neck Squamous Cell Carcinoma.
Li P; Wen X; Zhang X; Wang F; Zhang D; Shang H
Genet Test Mol Biomarkers; 2022 Dec; 26(12):553-563. PubMed ID: 36577127
[No Abstract] [Full Text] [Related]
37. Identification of Gene-Tyrosine Kinase 2 (TYK2) in Head and Neck Squamous Cell Carcinoma Patients-An Integrated Bioinformatics Approach.
Gong X; Ren F
Dis Markers; 2022; 2022():5239033. PubMed ID: 35711568
[TBL] [Abstract][Full Text] [Related]
38. The Immune Infiltration in HNSCC and Its Clinical Value: A Comprehensive Study Based on the TCGA and GEO Databases.
Sun X; Zhang L; Liu S
Comput Math Methods Med; 2021; 2021():1163250. PubMed ID: 34790249
[TBL] [Abstract][Full Text] [Related]
39. Transcriptome analysis reveals the link between lncRNA-mRNA co-expression network and tumor immune microenvironment and overall survival in head and neck squamous cell carcinoma.
Zhong Z; Hong M; Chen X; Xi Y; Xu Y; Kong D; Deng J; Li Y; Hu R; Sun C; Liang J
BMC Med Genomics; 2020 Mar; 13(1):57. PubMed ID: 32228580
[TBL] [Abstract][Full Text] [Related]
40. A TP53 mutation model for the prediction of prognosis and therapeutic responses in head and neck squamous cell carcinoma.
Shi C; Liu S; Tian X; Wang X; Gao P
BMC Cancer; 2021 Sep; 21(1):1035. PubMed ID: 34530752
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
